MORRISVILLE, N.C., April 25, 2019 – A clinical review article that describes the history and evolution of MyoStrain® was published in the ESC Heart Failure journal. The Manuscript, titled: “Strain‐encoded magnetic resonance: a method for the assessment of myocardial deformation”, summarizes the existing literature on the MyoStrain technology and its predecessor technologies, which totals over 250 prior articles. The technology has evolved and improved from HARP to SENC to, now, fast-SENC (MyoStrain).
The link to the manuscript is provided below:
Citation: Korosoglou G, et al. Strain-encoded Magnetic Resonance: A Method for the Assessment of Myocardial Deformation. ESC Heart Failure. 2019:1-19. doi:10.1002/ehf2.12442.
About Myocardial Solutions, Inc.
Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.
To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.